Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Rocket Pharmaceuticals, Inc. Warrant (RCKTW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: RCKTW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -89.92% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.02 - 0.15 | Updated Date 02/26/2025 |
52 Weeks Range 0.02 - 0.15 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Rocket Pharmaceuticals, Inc. Warrant
Company Overview
History and Background
Rocket Pharmaceuticals is a clinical-stage biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. Founded in 2015, the company went public in 2017.
Core Business Areas
- Gene Therapy Development: Development of gene therapies for inherited disorders, using adeno-associated virus (AAV) vectors to deliver corrected genes to patients.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its gene therapy candidates across various target diseases.
- Manufacturing: Investing in manufacturing capabilities to support the production of gene therapy products for clinical and commercial supply.
Leadership and Structure
The company is led by a management team with experience in gene therapy development and commercialization. The organizational structure includes research and development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- RP-A501 (Danon Disease): AAV9-based gene therapy for Danon Disease. It is currently in clinical trials. Competitors include potential future gene therapies or enzyme replacement therapies developed by other pharmaceutical companies. Currently no approved therapies.
- RP-L201 (LAD-I): AAV9-based gene therapy for Leukocyte Adhesion Deficiency-I (LAD-I). It is currently in clinical trials. Competitors include potential future gene therapies or bone marrow transplantation. Currently no approved therapies.
- RP-L102 (Fanconi Anemia Group A): Lentiviral vector-based gene therapy for Fanconi Anemia Group A (FA-A). Competitors include potential future gene therapies or bone marrow transplantation and androgen therapy. Currently no approved therapies for FA-A.
Market Dynamics
Industry Overview
The gene therapy industry is rapidly evolving, with increasing regulatory approvals and investment. The focus is on developing potentially curative therapies for genetic diseases. High unmet medical need drives significant market opportunity.
Positioning
Rocket Pharma is positioned as a key player in the rare disease gene therapy space, with a pipeline of promising candidates targeting unmet medical needs. They are focused on AAV and lentiviral vector platforms.
Total Addressable Market (TAM)
The total addressable market for gene therapies targeting rare diseases is estimated to be in the billions of dollars. Rocket Pharma's TAM is dependent on regulatory approvals and market penetration, with initial targets likely in the hundreds of millions per disease, growing with expanded indications.
Upturn SWOT Analysis
Strengths
- Strong pipeline of gene therapy candidates
- Experienced management team
- Focus on rare and unmet medical needs
- Proprietary gene therapy platform
Weaknesses
- Clinical trial risk
- Manufacturing complexity
- Regulatory hurdles
- High development costs
Opportunities
- Expanding pipeline to new indications
- Securing regulatory approvals
- Partnering with other companies
- Advancing manufacturing capabilities
Threats
- Competition from other gene therapy companies
- Adverse clinical trial results
- Changes in regulatory landscape
- Pricing and reimbursement challenges
Competitors and Market Share
Key Competitors
- BLUE
- CRSP
- EDIT
- BEAM
- AVRO
Competitive Landscape
The gene therapy landscape is highly competitive. Rocket Pharma competes with other gene therapy companies, as well as companies developing alternative treatments for rare diseases. Success depends on clinical trial outcomes, regulatory approvals, and commercial execution.
Growth Trajectory and Initiatives
Historical Growth: Growth is tied to the clinical development and regulatory approval of its gene therapy programs.
Future Projections: Future growth is highly dependent on clinical trial success and regulatory approvals. Analyst estimates vary widely, with potential for significant upside upon positive clinical data readouts.
Recent Initiatives: Recent initiatives include advancing clinical trials for lead programs and expanding manufacturing capabilities.
Summary
Rocket Pharmaceuticals is a clinical-stage company in the gene therapy space focused on rare diseases. They have a promising pipeline and experienced management, but also face significant clinical trial and regulatory risks. Positive clinical data and regulatory approvals are crucial for future success. While the warrants offer leveraged exposure, they also carry high risk due to their derivative nature and dependence on Rocket Pharmaceuticals' stock performance.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise. The value of warrants is speculative and carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rocket Pharmaceuticals, Inc. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-02-27 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 240 | Website |
Full time employees 240 | Website | ||
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.